Laga assisted Miracor on all legal and tax aspects, including negotiations for the equity and debt financing round, of the transfer of its Austrian activities to Belgium, and the merger of the respective entities.
The parties involved included several investment funds (European and Chinese), an industrial U.S. company, the Walloon Region (SRIW and Meusinvest) and the Belgian State (SFPI) which all invested in the company. This move also shows the Walloon Region’s attractiveness for medtech and biotech companies.
The clinical results, which are conclusive, still need to be confirmed by a final randomised study in Europe before the product is launched on the market in 2019. With this in mind, the Austrian company, which is specialised in medical equipment, made the decision to raise €25 million.
Laga’s extensive team was headed by Benoît Féron (picture) and Anne Tilleux from the Corporate – M&A practice, and Eric Von Frenckell for the Tax aspects, and included Julie Salteur, William Hollanders, Alexandre Pasdermadjian, Gauthier Davignon, Marie Vanclaire and Justine Smeets.
Involved fees earner: Benoît Féron – Laga; Anne Tilleux – Laga; Julie Salteur – Laga; William Hollanders de Ouderaen – Laga; Alexandre Pasdermadjian – Laga; Gauthier Davignon – Laga; Marie Vanclaire – Laga; Eric von Frenckell – Laga; Justine Smeets – Laga;
Law Firms: Laga;
Clients: Miracor Medical;